Routine viral load monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India

Chinmay Laxmeshwar, Shrikala Acharya, Mrinalini Das, Padmaja Keskar, Amar Pazare, Nayana Ingole, Preeti Mehta, Pooja Gori, Homa Mansoor, Stobdan Kalon, Pramila Singh, Taanya Mathur, Gabriella Ferlazzo, Petros Isaakidis

1 Médecins Sans Frontières, Mumbai, India, 2 Mumbai Districts AIDS Control Society, Mumbai, India, 3 KEM Hospital, Mumbai, India, 4 Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa

* chinmay2210@gmail.com

Abstract

Background
Routine viral-load (VL) measurements along with enhanced adherence counselling (EAC) are recommended to achieve virological suppression among people living with HIV/AIDS (PLHA) on anti-retroviral therapy (ART). The Mumbai Districts AIDS Control Society along with Médecins Sans Frontières has provided routine VL measurements and EAC to PLHA on ART at King Edward Memorial (KEM) hospital, Mumbai since October-2016. This study aims to describe the initial VL results and impact of EAC on viral suppression and factors associated with initial viral non-suppression among patients with an initial detectable VL, in a cohort of patients tested between October-2016 and September-2018.

Methods
This is a descriptive study of PLHA on ART who received VL testing and EAC during October-2016 to September-2018. Log-binomial regression was used to identify factors associated with a high VL.

Results
Among 3849 PLHA who underwent VL testing, 1603(42%) were female and median age was 42 years (IQR:35–48). Majority were referred for routine testing (3432(89%)) and clinical/immunological failure (233(6%)). Overall, 3402(88%) PLHA had suppressed VL at initial testing. Among 291 with VL >1000c/ml, 253(87%) received EAC and after repeat VL, 70(28%) had VL <1000c/ml. Among 233 referred for clinical/immunological failure, 122(52%) had VL >1000c/ml and 109 have been switched to second-line ART.

CD4 count<500 (aOR=5.0[95%CI 3.8–6.5]), on ART for<5 years (aOR=1.5[1.1–2.0]) and age<15 years (aOR=5.2[3.0–8.9]) were associated with an initial VL>1000c/ml.
associated with follow-up VL suppression included EAC (p<0.05) and being on second-line ART (p<0.05).

**Conclusion**

Results from a routine VL program in public sector in India were encouraging and in line with UNAIDS 90-90-90 targets. Routine VL monitoring along with EAC resulted in early switch to alternative optimised regimens while also preventing unnecessary switches. Along with the vital scale up of routine VL monitoring, implementation of enhanced adherence strategies for patients with detectable viral load should be ensured.

**Introduction**

The HIV/AIDS epidemic continues with 36.9 million people living with HIV/AIDS (PLHA) globally in 2017 [1]. India, with an estimated 2.1 million PLHA had the third highest number of PLHA in the world in 2015 [2]. Coverage of antiretroviral therapy (ART) is increasing with 21.7 million PLHA worldwide on ART in 2017 [1]. In India, about 1.1 million PLHA were estimated to be on ART in 2015 [3]. India is committed to achieve the UNAIDS 90-90-90 targets, which specify that 90% of PLHA should know their HIV status, 90% diagnosed with HIV should be on ART and 90% of those on ART should have viral suppression [3,4].

To achieve this viral suppression, routine HIV viral load (VL) monitoring is necessary. The World Health Organization (WHO) recommends VL as the preferred approach to ART monitoring compared to clinical or immunological criteria [5]. This is due to the fact that a decrease in CD4 count, which is a marker of immunological failure, occurs as result of viral replication, which can thus be considered as an endpoint [6]. Routine VL has been shown to lead to earlier detection of treatment failure compared to immunological and clinical criteria. This can lead to prompt and correct switches to optimised second or third line ART, which in turn can improve treatment outcomes [7,8]. Routine VL testing can also help prevent unnecessary switches to second-line or third-line ART [9].

From a drug-resistance perspective, early detection of unsuppressed viral load and treatment failure through routine VL measurement can contribute to prevent accumulation of thymidine analogue mutations, which have the potential to reduce the effectiveness of second-line ART regimens [9–12]. Development of HIV drug-resistance is a serious issue for HIV control programs and can wipe out the gains made so far [13,14]. This would also lead to increased costs for HIV programs, which would be a high burden for low resource settings [8,12]. Mathematical modelling has shown that use of routine VL can also lead to reduced HIV transmission [15].

Along with identifying failures, routine VL has also been shown to help with adherence [9,16–18]. It has been postulated that just being informed about a high viral load has positive effect on adherence of a patient [19]. Adherence counselling encourages patients to discuss barriers to treatment and develop a plan accordingly with the counsellor. WHO recommends adherence support between two VL measurements in order to define failure [20]. Use of routine VL coupled with enhanced adherence counselling has shown to lead to optimal utilisation of ART services, with improved outcomes among patients [19].

Routine VL testing in India is was launched in 2018 [3]. The National AIDS Control Organisation (NACO) has recommended in 2018 the use of routine VL monitoring with the aim to identify patients with early treatment failure and those in need switch to optimised ART
regimen. Adherence support has also been planned by providing three counselling sessions to patients with detectable VL, provision of a case manager and if necessary daily supervised ingestion of treatment [3]. Prior to the introduction of these national guidelines, in 2016, Mumbai Districts AIDS Control Society (MDACS) and the international humanitarian non-governmental organisation Médecins Sans Frontières (MSF) started providing routine viral load measurements and enhanced adherence counselling to a cohort of patients taking ART at King Edward Memorial (KEM) hospital in Mumbai. This study was conducted with an aim to describe the initial viral load, the impact of enhanced adherence counselling on VL suppression for patients with VL >1000 c/ml and the factors associated with initial viral non-suppression among PLHA tested between October 2016 and September 2018.

Methods

Study design

This is a descriptive study using routinely collected programme data.

Setting

Mumbai is a megacity in Maharashtra, India with a population of about 12.5 million people [21]. The city is home to 25% of PLHA in the state. The Mumbai Districts AIDS Control Society is responsible for implementation of the National AIDS Control Program in the city. In 2015, there were 75,220 PLHA registered with MDACS while 62% among them were on active care [22]. ART is provided through 14 ART centres spread across the city. First- and second-line ART are available at all centres while third-line ART is available at the Centre of Excellence at Sir J.J. group of hospitals.

The ART centre at King Edward Memorial (KEM) hospital is a high burden centre providing services to about 4200 PLHA. The centre provides first- and second line ART. All regimens are designed as per national guidelines [23]. The centre is manned by doctors, nurses, counsellors, peer educators and pharmacist. Clinical decision making is supported by a District AIDS Clinical Expert Panel (DACEP). Any changes to ART regimens can be made only by this panel.

Since October 2016, MDACS along with MSF has been providing VL monitoring along with enhanced adherence counselling for PLHA on ART at KEM hospital. PLHA on ART for more than 6 months or those with signs of clinical failure were eligible for VL measurement. In case the VL was more than 1000 c/ml, then the PLHA was referred to a counsellor for enhanced adherence counselling spread over three months before VL was retested. It was recommended that at least one EAC session be conducted with the patient upon receiving a high viral load result and before retesting. The first session would be offered the same day the viral load result was received. The second session was offered one month later and before the 2nd viral load. More sessions could be offered, according to the patient’s needs.

Enhanced adherence counselling followed the motivation-information-be haviour skill model. During the first session, patients with high viral load were invited during the counselling sessions to assess the barriers they face in adherence to their treatment. The counsellor helps the patient assess the information and motivation level of the patient and serves as a facilitator to fill the relevant gaps. In addition to providing information about HIV and viral load, providing emotional support is a very important component of EAC, as many patients report facing stigma, feeling depressed/or suffering from other mental health problems. Keeping all this in mind, an individualized adherence plan is developed which further enables the patient to take their treatment successfully. The second EAC session focuses on reviewing the plan.
with the patient and supporting them, where required. The end goal for EAC is to ensure that patients take their medication timely and in an effective manner.

Post EAC, the VL was retested, three months after the first measurement. In case the VL result was still more than 1000c/ml, then the patient was referred to the District AIDS Clinical Expert Panel (DACEP) in KEM hospital. The panel would decide on the appropriate ART regimen based on national guidelines. Patients may be referred directly to DACEP in case of clinical/immunological failure. Patients referred for presumptive clinical/immunological failure also underwent viral load testing. However, their regimen could be changed by DACEP even before EAC and repeat VL testing, based on clinical criteria under the national guideline.

For all patients with suppressed VL, national guidelines now recommend routine VL monitoring, to be repeated once a year. Standard WHO definitions were used for defining clinical, immunological and virological failure (Table 1) [24].

VL were done using Xpert HIV-1 Viral Load (Cepheid) platform.

**Study population**

All PLHA tested for HIV-VL, irrespective of the reason for testing (routine, clinical/immunological failure and other reasons), between October 2016 and September 2018 were included in this study.

**Data collection and variables**

Details of all patients who underwent VL testing were captured by a nurse in patient cards at the ART centre. The data then was entered into a Microsoft Excel 2010 database by a dedicated data encoder. Socio-demographic variables, ART regimen and CD4 counts were captured from patient cards. VL result was entered from lab reports. Dates of EAC were provided by the counsellor to the data encoder and were entered in a Microsoft Excel 2010 database. A cut-off date of 31 December 2018 was used for follow-up viral load and regimen switches.

**Data analysis**

Data was imported into SPSS (Version 20, 2011; IBM Inc., Chicago, IL, USA) for analysis. Categorical variables among the socio-demographic characteristics of the study participants were described using numbers and proportions, and continuous variables described using median and inter quartile range (IQR). Bivariate analysis was conducted to study the relationships between demographic and select variables with VL $>1000$ copies/ml. Those with a p-value of less

**Table 1. WHO definitions of clinical, immunological and virological failures.**

| Type of failure       | Definition                                                                                   |
|-----------------------|---------------------------------------------------------------------------------------------|
| Clinical failure      | Adults and adolescents—New or recurrent clinical event indicating severe immunodeficiency  |
|                       | (WHO clinical stage 4 condition) after 6 months of effective treatment.                       |
|                       | Children—New or recurrent clinical event indicating advanced or severe immunodeficiency     |
|                       | (WHO clinical stage 3 and 4 clinical condition with the exception of TB) after 6 months of   |
|                       | effective treatment.                                                                        |
| Immunological failure | Adults and adolescents—CD4 count at or below 250 cells/mm$^3$ following clinical failure OR |
|                       | persistent CD4 levels below 100 cells/mm$^3$.                                               |
|                       | Children $<5$ years—Persistent CD4 levels below 200 cells/mm$^3$.                            |
|                       | Children $>5$ years—Persistent CD4 levels below 100 cells/mm$^3$.                            |
| Virological failure   | Among patients on ART for more than six months, virological failure is viral load above 1000|
|                       | copies/ml based on two consecutive viral load measurements in 3 months, with adherence      |
|                       | support following the first viral load test.                                                 |

https://doi.org/10.1371/journal.pone.0232576.t001
than 0.2 were included in the multivariate model along with factors considered clinically and epidemiologically significant. Log binomial regression was used to identify factors associated with VL > 1000c/ml. A p-value of 0.05 or below was considered statistically significant.

**Ethics**

Approval was obtained from the Mumbai Districts AIDS Control Society for conducting this study (Reference number MDACS/10383/PD dated 15th February 2018). This research also fulfilled the exemption criteria set by the Médecins Sans Frontières Ethics Review Board (Geneva, Switzerland) for a posteriori analyses of routinely collected clinical data and thus did not require MSF ERB review. It was conducted with permission from Medical Director, Operational Centre Brussels, Médecins Sans Frontières. All data was anonymised before it was obtained for analysis.

**Results**

A total of 3849 PLHA were tested for HIV viral load during the study period. Median age was 42 years (IQR – 35–48 years) and 42% were female. Socio-demographic and clinical characteristics of the patients are described in Table 2.

**HIV viral load cascade**

Among all the viral load tests, 3432 (89%) were done for routine monitoring, 233 (6%) were done for presumptive clinical/immunological failure, while 184 (5%) were done for other reasons. The viral load testing cascade has been described in Fig 1. Overall, 3402 (88%) of patients tested were found to have a VL < 1000c/ml. Among those tested for routine monitoring, 92% (3141/3432) had VL less than 1000c/ml, while among those tested because of clinical/immunological failure, 48% (111/233) had a VL < 1000c/ml. Those with clinical/immunological failure and VL < 1000c/ml were maintained on the same regimen while adherence was reinforced by

| Table 2. Socio-demographic and clinical characteristics of PLHA tested for HIV viral load at ART centre, KEM hospital, Mumbai during October 2016 – September 2018. |
|-------------------------------------------------|--------------------------|
| Number tested for HIV-VL* | 3849 |
| Median Age (IQR*) | 42 (35–48) |
| Sex |  |
| Male | 2246 (58) |
| Female | 1603 (42) |
| ART regimen |  |
| First line ART | 3648 (95) |
| Alternative first line ART | 76 (2) |
| Second line ART | 125 (3) |
| Reason for referral |  |
| Routine testing | 3432 (89) |
| Clinical/immunological failure | 233 (6) |
| Other | 184 (5) |
| Median CD4 (IQR) (n = 3811) | 517 (360–699) |
| Median time on ART in months (IQR) (n = 3832) | 40 (23–60) |

* VL–Viral load
* IQR–Inter quartile range
* ART–Anti retroviral therapy

https://doi.org/10.1371/journal.pone.0232576.t002
use of EAC. Among the 291 tested for routine VL testing who had VL > 1000 c/ml, 253 (87%) attended at least one EAC during the study period and underwent VL retesting after at least 3 months. Among 253 who underwent EAC, 20 (8%) underwent one EAC session, 123 (48%) two sessions and 111 (44%) three or more sessions. After EAC, 70 (28%) had their VL suppressed and were kept on the same ART regimen. The remaining 183 (72%) were declared treatment failure and referred for ART switch. Among these, 140 (77%) were effectively switched during the study period.

Factors associated with initial HIV viral load

In bivariate analysis, age (p < 0.001), time on the ART (p < 0.001), CD4 count (p < 0.001) and reason for referral (p < 0.001) were significantly associated with high initial viral load. Sex (p = 0.179) was not seen to be significantly associated with initial VL.

In multivariate analysis (Table 3), age < 15 years, less than 5 years on ART, CD4 count less than 500 and being referred for clinical/immunological failure were seen to be associated with baseline VL > 1000 c/ml.

Factors associated with post EAC viral load suppression among those tested for routine testing

Among those referred for routine VL testing and who had a baseline VL of more than 1000 c/ml, post EAC, 253 had a repeated VL testing after 3 months (Fig 1). Number of EAC sessions...
was seen to have a statistically significant association with VL suppression (p < 0.05). Among those who received only 1 EAC, 10 (50%) had their VL suppressed on repeat testing. While for those who had received more than 1 EAC only 60 (26%) had their VL suppressed. Also, patients on second-line ART were seen to have significantly (p = 0.015) better suppression (7, 58%) compared to those on first-line ART (63, 26%).

**Table 3. Factors affecting initial VL among patients on ART at KEM hospital, Mumbai.**

| Variable                  | Viral load | Risk ratio (95% CI) |
|---------------------------|------------|---------------------|
|                           | >1000c/ml n (%) | <1000 c/ml n (%) | Total |                      |
| Age                       |            |                     |       |                       |
| < = 15 years              | 27 (25)    | 79 (75)             | 106   | 5.16 (2.99–8.88)*     |
| 16–45 years               | 290 (12)   | 2159 (88)           | 2449  | 1.29 (1.01–1.66)*     |
| >45 years                 | 130 (10)   | 1164 (90)           | 1294  | 1                       |
| Sex                       |            |                     |       |                       |
| Male                      | 274 (12)   | 1972 (88)           | 2246  | 1                       |
| Female                    | 173 (11)   | 1430 (89)           | 1603  | 1.03 (0.82–1.31)       |
| Reason for referral       |            |                     |       |                       |
| Routine                   | 291 (8)    | 3141 (92)           | 3432  | 1                       |
| Clinical/immunological failure | 122 (52) | 111 (48)            | 233   | 8.13 (6.03–10.96)*     |
| Other                     | 34 (18)    | 150 (82)            | 184   | 1.62 (1.01–2.59)*      |
| Duration on ART           |            |                     |       |                       |
| >5 years                  | 74 (8)     | 875 (92)            | 949   | 1                       |
| <5 years                  | 363 (13)   | 2520 (87)           | 2883  | 1.47 (1.1–1.98)*       |
| CD4 count (cells/mm³)     |            |                     |       |                       |
| >500                      | 81 (4)     | 1923 (96)           | 2004  | 1                       |
| <500                      | 359 (20)   | 1448 (80)           | 1807  | 5.01 (3.82–6.56)*      |

* - p < 0.05

https://doi.org/10.1371/journal.pone.0232576.t003

Discussion

The study shows a virological suppression of 88% in the KEM hospital cohort at the beginning of the intervention, while a suppression of 92% was observed among the subgroup of patients tested for routine monitoring. These are very encouraging findings and in line with the target of 90% virological suppression set by UNAIDS. Among patients tested for routine monitoring and who had VL>1000c/ml, 28% had a follow-up VL<1000c/ml and their ART regimen was maintained, while the rest were referred for switch to second-line ART regimen. Almost 77% of those referred were switched during the study period. Among those tested for clinical/immunological failure, almost half had VL<1000c/ml and their regimens were maintained, as per national guidelines, thus preventing unnecessary switches. The role of routine viral load in earlier identification of failures and, earlier switches to second-line ART and improved treatment outcomes, while at the same time preventing unnecessary switches has been reported by many studies around the world [6–14,16–19,25–31].

Multivariate analysis revealed that age less than 15 years was significantly associated with a higher VL. Many studies around the world have reported lower age as a risk factor for higher VL [16,32,33]. Maintaining adherence among adolescents and children is a well-recognised challenge [34]. Viral suppression has been reported to be low in these age groups even post counselling [35]. Hence, it is important that special attention is given to these age groups. Context specific and age specific interventions might help improve adherence and thus response to
treatment in this vulnerable group. Immunological status, evidenced by CD4 count was also
seen to be associated with VL, with PLHA with CD4 less than 500 showing more virological
failure than those with CD4 count more than 500. This result is in concordance with multiple
studies reporting similar findings [10,19,36].

Among those with baseline VL >1000c/ml, follow-up viral suppression was significantly
associated with EAC. Many studies around the world have proved effectiveness of EAC in
helping patients adhere to their treatment and thus leading to a decreased VL. A study from
Swaziland had reported 61% suppression post-EAC [19], while another study from South
Africa reports a 41% post-EAC suppression [10]. In our study, looking at the number of EAC
sessions and its effect on VL suppression, it was observed that those who had only one session
showed better suppression than those who had more than one. This might be because only
those who had a higher degree or long-standing adherence issues might have been selected for
more than one session. Previous studies have reported that it is the support rather than the
number of sessions which lead to improved adherence [19]. Thus, while introducing routine
viral load, programs should also pay enough attention on adherence counselling and support.
Follow-up viral suppression was also higher in those on second-line ART, which follows a
study done in Uganda [33].

The strengths of this study include that it reports a large cohort of PLHA on ART at a high
burden public ART centre. The participants in this study received access to routine VL before
the release and implementation of national guidelines, and thus represent one of the earliest
cohorts in the country to receive access to routine VL. While patients received VL testing, they
were also adequately supported to improve their adherence by a trained counsellor. However,
the follow-up period for the patients was short, which is a limitation of this study. Providing
routine VL and EAC over a longer period should inform about the long term efficacy and
effectiveness of EAC in the population.

In conclusion, viral suppression among PLHA on ART was in line with the UNAIDS 90-
90-90 targets in the study cohort. The use of routine viral load led to early identification of
treatment failures and referrals to second- and third-line regimens, while also preventing
unnecessary switches. Enhanced adherence counselling played a significant role in viral load
suppression among those identified with a high initial viral load. While scaling up the essential
access to viral load monitoring and ensuring rapid switch to second- and third-line ART regi-
mens for failing patients, national HIV programmes should put efforts in the integration of
adherence support strategies for the best results and adequate resource utilisation.

Acknowledgments

The authors would like to acknowledge all study participants and staff at ART centre, KEM
Hospital and MDACS for their support.

Author Contributions

Conceptualization: Chinmay Laxmeshwar, Shrikala Acharya, Mrinalini Das, Padmaja Keskar,
Homa Mansoor, Stobdan Kalon, Gabriella Ferlazzo, Petros Isaakidis.

Data curation: Chinmay Laxmeshwar, Mrinalini Das.

Formal analysis: Chinmay Laxmeshwar, Mrinalini Das, Petros Isaakidis.

Investigation: Chinmay Laxmeshwar, Shrikala Acharya, Amar Pazare, Nayana Ingole, Preeti
Mehta, Pooja Gori, Pramila Singh, Taanya Mathur.
Methodology: Chinmay Laxmeshwar, Shrikala Acharya, Mrinalini Das, Amar Pazare, Preeti Mehta, Homa Mansoor.

Project administration: Shrikala Acharya, Padmaja Keskar, Amar Pazare, Nayana Ingole, Pooja Gori, Stobdan Kalon, Pramila Singh, Taanya Mathur.

Resources: Stobdan Kalon, Taanya Mathur.

Supervision: Chinmay Laxmeshwar, Shrikala Acharya, Padmaja Keskar, Amar Pazare, Preeti Mehta, Pooja Gori, Pramila Singh, Taanya Mathur.

Validation: Homa Mansoor, Stobdan Kalon, Taanya Mathur, Gabriella Ferlazzo, Petros Isaakidis.

Writing – original draft: Chinmay Laxmeshwar, Mrinalini Das.

Writing – review & editing: Shrikala Acharya, Padmaja Keskar, Amar Pazare, Nayana Ingole, Preeti Mehta, Pooja Gori, Homa Mansoor, Stobdan Kalon, Pramila Singh, Taanya Mathur, Gabriella Ferlazzo, Petros Isaakidis.

References
1. UNAIDS. 2017 GLOBAL HIV STATISTICS. 2018. Available: http://www.unaids.org/en/resources/fact-sheet
2. National AIDS Control Organisation. National Guidelines for HIV-1 Viral Load Laboratory Testing. 2018. Available: http://naco.gov.in/sites/default/files/NationalGuidelinesForHIV-1ViralLoadLaboratoryTestingApril2018%282%29.pdf
3. National AIDS Control Organisation. National operational guidelines for viral load testing. 2018. https://doi.org/10.1016/S0168-8278(06)80734-8
4. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. 2014. Available: http://www.unaids.org/Sites/Default/Files/Media_Aset/90-90-90_En_0.Pdf
5. WHO. HIV / AIDS 7.3 Monitoring response to ART and the diagnosis of treatment failure. [cited 13 Feb 2018]. Available: http://www.who.int/hiv/pub/guidelines/av2013/art/artmonitoring/en/index3.html
6. Saag MS, Holodniy M, Kuritzkes DR, O’Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med. 1996; 2: 625–629. https://doi.org/10.1038/rnm0696-625 PMID: 8640545
7. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: a randomised trial. BMJ. 2011; 343: d6792–d6792. https://doi.org/10.1136/bmj.d6792 PMID: 22074711
8. The ART-LINC of IeDEA Study Group. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009; 23: 1867–1874. https://doi.org/10.1097/QAD.0b013e32832e05b2 PMID: 19531928
9. Sigaloff KCE, Hamers RL, Wallis CL, Kityo C, Siwale M, Ipe P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011; 58: 23–31. https://doi.org/10.1097/QAI.0b013e318227fc34 PMID: 21694603
10. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, et al. Viremia, resuppression, and the time to resistance in HIV subtype C during first line antiretroviral therapy in South Africa. Clin Infect Dis. 2008; 49: 1928–1935. https://doi.org/10.1086/494444 PMID: 19911983
11. Stadell KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2015; 18: 115–123. https://doi.org/10.3851/IMP2437.-Rates
12. Barth RE, van der Loef MFS, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010; 10: 155–166. https://doi.org/10.1016/S1473-3099(09)70328-7 PMID: 20185094
13. Hingankar NK, Thorat SR, Deshpande A, Rajasekaran S, Chandrasekar C, Kumar S, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis. 2012; 54. https://doi.org/10.1093/cid/cis005 PMID: 22544202
14. Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to
second-line antiretroviral regimens in resource-limited settings. AIDS. 2011; 25: 843–850. https://doi.org/10.1097/QAD.0b013e328344037a PMID: 2192233

15. Estill J, Aubriere C, Egger M, Johnson L, Wood R, Garone D, et al. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: A mathematical modelling analysis. AIDS. 2012; 26: 1403–1413. https://doi.org/10.1097/QAD.0b013e328356988 PMID: 22421243

16. Billioux A, Nakigozi G, Newell K, Chang LW, Quinn TC, Gray RH, et al. Durable suppression of HIV-1 after virologic monitoring-based antiretroviral adherence counseling in Rakai, Uganda. PLoS One. 2015; 10: 1–8. https://doi.org/10.1371/journal.pone.0127235 PMID: 26011158

17. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009; 9: 409–417. https://doi.org/10.1016/S1473-3099(09)70136-7 PMID: 19555900

18. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral Load Monitoring as a Tool to Reinforce Adherence. JAIDS J Acquir Immune Defic Syndr. 2013; 64: 74–78. https://doi.org/10.1097/QAI.0b013e31829f05ac PMID: 2374877

19. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Jouquet G, et al. Impact and programmatic implications of routine viral load monitoring in swaziland. J Acquir Immune Defic Syndr. 2014; 67: 45–51. https://doi.org/10.1097/QAI.0000000000000224 PMID: 24872139

20. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. 978 92 4 150572 7

21. Census. Mumbai (Greater Mumbai) City Population Census 2011 | Maharashtra. In: Office of the Registrar General and Census Commissioner, India [Internet]. [cited 3 Mar 2016]. Available: http://www.census2011.co.in/census/city/365-mumbai.html

22. Mumbai Districts AIDS Control Society. Care and Support and Treatment. [cited 14 Feb 2018]. Available: http://mdacs.org.in/

23. National AIDS Control Organisation. National technical guidelines on antiretroviral treatment. 2018. Available: http://naco.gov.in/sites/default/files/NACO - National Technical Guidelines on ART_October 2018%281%29.pdf

24. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Heal Organ. 2016; 155 p.

25. Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, et al. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis. 2014; 58: 1022–1026. https://doi.org/10.1093/cid/cit933 PMID: 24352348

26. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect Dis. 2016; 62: 1043–1048. https://doi.org/10.1093/cid/ciw001 PMID: 26743094

27. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Heal. 2009; 14: 1220–1225. https://doi.org/10.1111/j.1365-3156.2009.02338.x Accuracy

28. Ingole N, Mehta P, Paware A, Paranjpe S, Sarkate P. Performance of Immunological Response in Predicting Virological Failure. AIDS Res Hum Retroviruses. 2013; 29: 541–546. https://doi.org/10.1089/AID.2012.0266 PMID: 23137294

29. Keiser O, Chi BH, Gsponer T, Boule A, Orrell C, Phiri S, et al. Outcomes of Antiretroviral Treatment in Programmes with and without Routine Viral Load Monitoring in Southern Africa. AIDS. 2011; 25: 1761–1769. https://doi.org/10.1097/QAD.0b013e328349822f PMID: 21681057

30. Laurent C, Kouanfack C, Laborde-Balen G, Agboke AF, Mbougoua JBT, Boyer S, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): A randomised non-inferiority trial. Lancet Infect Dis. 2011; 11: 825–833. https://doi.org/10.1016/S1473-3099(11)70168-2 PMID: 21831714

31. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007; 44: 128–134. https://doi.org/10.1086/510073 PMID: 17143828

32. O’Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017; 4: e295–e302. https://doi.org/10.1016/S2352-3018(17)30053-X PMID: 28479492
33. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017; 17: 1–11. https://doi.org/10.1186/s12879-016-2122-x

34. Ferrand RA, Briggs D, Ferguson J, Penazzato M, Armstrong A, Macpherson P, et al. Viral suppression in adolescents on antiretroviral treatment: Review of the literature and critical appraisal of methodological challenges. Trop Med Int Heal. 2016; 21: 325–333. https://doi.org/10.1111/tmi.12656 PMID: 26681359

35. Nasuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, Nakanjako D. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018; 18: 1–9. https://doi.org/10.1186/s12889-018-5964-x PMID: 30134880

36. Rangarajan S, Donn JC, Giang LT, Bui DD, Hung Nguyen H, Tou PB, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J virus Erad. 2016; 2: 94–101. https://doi.org/10.1016/j.neulet.2015.10.060 PMID: 27482442